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Abstract
Background: Although the introduction of combined therapy with reverse transcriptase and protease inhibitors has
resulted in considerable decrease in HIV related mortality; it has also induced the development of multiple drug-resistant
HIV-1 variants.
The few studies on HIV-1 mutagenesis in HIV infected children have not evaluated the impact of HIV-1 mutations on the
clinical, virological and immunological presentation of HIV disease that is fundamental to optimizing the treatment
regimens for these patients.
Results: A cross sectional study was conducted to evaluate the impact of treatment regimens and resistance mutation
patterns on the clinical, virological, and immunological presentation of HIV disease in 41 children (25 male and 16 female)
at the Robert Wood Johnson Pediatric AIDS Program in New Brunswick, New Jersey. The study participants were
symptomatic and had preceding treatment history with combined ARV regimens including protease inhibitors (PIs),
nucleoside reverse transcriptase inhibitors (NRTIs) and non-nucleoside reverse transcriptase inhibitors (NNRTIs).
Fifteen (36.6%) children were treated with NRTI+NNRTI+ PI, 6 (14.6%) with NRTI+NNRTIs, 13 (31.7%) with NRTI+PIs,
and the remaining 7 (17.1%) received NRTIs only.
Combined ARV regimens did not significantly influence the incidence of NRTI and NNRTI associated mutations. The
duration of ARV therapy and the child's age had no significant impact on the ARV related mutations. The clinico-
immunological presentation of the HIV disease was not associated with ARV treatment regimens or number of resistance
mutations. However, primary mutations in the protease (PR) gene increased the likelihood of plasma viral load (PVL) ≥
10,000 copies/mL irrespective of the child's age, duration of ARV therapy, presence of NRTI and NNRTI mutation.
Viremia ≥ 10,000 copies/mL was recorded in almost all the children with primary mutations in the PR region (n = 12/13,
92.3%) as compared with only 50.0% (n = 14/28) of HIV infected children without (PR-), P < 0.008. However, CD-4 T
cells were not affected by the mutations in the PR gene of the HIV-1 isolates.
Conclusion: Primary PR resistance mutations significantly increase the likelihood for high viral replication in pediatric
patients with moderate/severe HIV-1 infection, which may affect the long-term clinical prognosis of the HIV infected
children.
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Background
Antiretroviral drug resistance produced by drug associated
mutations in specific regions of the HIV genome has been
recognized as one major problem during the treatment of
human immunodeficiency virus type 1 (HIV-1) infected
patients [1,2]. It has been shown that antiretroviral ther-
apy used in the presence of drug-resistant viruses may
increase the risk of HIV-1 mutagenesis [2,3] and the
expansion of resistant HIV mutants compromises the effi-
cacy of the antiretroviral (ARV) therapy [4-6].
Numerous studies have described the association between
multiple mutations and multidrug resistance in HIV-1 iso-
lates in adults [3,7-10] but knowledge regarding this issue
in the population of HIV infected children is limited. We
previously reported the occurrence of mutations in the
protease (PR) gene in a small group of HIV infected chil-
dren treated with the protease inhibitor (PI) nelfinavir
[11]. HIV-1 mutants have been isolated both from both,
ARV treated and untreated HIV infected Brazilian children
[12] Several studies demonstrated that the failure of ARV
therapy [13] and clinical disease progression [14] in HIV
infected children is associated with a high frequency of
primary mutations in the reverse transcriptase (RT) gene.
Cognizance of the impact of resistance mutations on the
subsequent response to ARV therapy is of importance in
the optimization of treatment regimens, especially for
HIV-1 infected pediatric patients. The few studies pub-
lished on the subject of HIV mutagenesis in children do
not address the prime question regarding the extent to
which HIV-1 mutations impact the clinical, virological,
and immunological parameters of HIV disease in the
infected children.
We designed a cross-sectional study to assess the impact of
the development and association of drug resistant muta-
tions in the HIV-1 genome on the clinical, virological, and
immunological presentation of HIV infection in children
who were infected at birth.
Methods
An Institutional Review Board approved study was con-
ducted at the Robert Wood Johnson Medical School's
Pediatric Infectious Disease Clinic between 1999 and
2004. A total number of 42 HIV infected children were
enrolled, and 41 (97.6%) of those who completed the
required virological, immunological and HIV genotype
testing were included in the analysis.
Demographic and treatment related information (gender,
age of study entry, length and ARV treatment regimens)
was recorded for each subject. In order to provide more
prognostic information, plasma viral load (PVL) and
CD4+ T- lymphocyte counts were tested simultaneously
[15,16] using HIV-1 RNA assay flow cytometry [17,18].
Resistance mutations in the HIV genomes, both the RT
and the PR genes were examined in the plasma viral RNA
by reverse transcription and relevant genome segment
amplification (HIV GENOSURE™). The presence of resist-
ance-related mutations was classified in accordance with
the recommendations of the International AIDS Society-
USA [19] and International Expert Panel on HIV Antiret-
roviral Drug Resistance [20], and the 2005 update by
Johnson et al [21] regarding drug resistance mutations in
HIV-1 was also used.
The mutations associated with protease inhibitors (PIs),
nucleoside reverse transcriptase inhibitors (NRTIs) and
non-nucleoside reverse transcriptase inhibitors (NNRTIs)
as well as the individual point (single amino acid
changes) mutations were analyzed. Individual drug spe-
cific resistance and cross-resistance to one or more drugs
of the same class was also identified.
The collected clinical and immunologic data were catego-
rized in accord with the classification system for HIV-
infected children of less than 13 years of age [22] and ado-
lescents [23]. PVL cutoff of 10,000 copies/mL for initia-
tion of ARV therapy in adults and adolescents [24] was
used to evaluate viremia level <10,000 copies/mL and ≥
10,000 copies/mL.
Clinical, immunological, and virological data was statisti-
cally analyzed (Statistica 6.0, StatSoft, Tulsa, OK) with
respect to the treatment regimens and resistance muta-
tions. The Pearson chi-square or Fisher's exact tests were
performed for categorical data and Mann-Whitney test or
Analysis of Variance for continuous data. Odds ratio (OR)
and 95% confidence interval (95%CI) was calculated for
the association using results from the multivariate regres-
sion analysis. All the P values presented are two-tailed
with significance <0.05
Results
The 25 males and 16 females (n = 41) included in this
study were moderately or severely symptomatic [22,23] at
the time of study entry. The ARV treatment history showed
that all but one had received two or more NRTI group
medications (zidovudine, lamivudine, stavudine, didano-
sine, and zalcitabine). In addition, 21 (51.2%) children
were treated with one or two medications from the NNRTI
group (nevirapine, efavirenz) and 28 (68.3%) – with one
or two medications from the PI group (nelfinavir, ritona-
vir, indinivir, saquinavir). However, PI boosted regimens
were not used in the treatment of these patients. Overall,
the majority of the HIV-1 infected children in this study (n
= 34, 82.9%) had been treated with combined ARV regi-
mens, such as (i) NRTI+NNRTI+PI (n = 15, 36.6%), (ii)
NRTI+NNRTI (n = 6, 14.6%) and (iii) NRTI+PI (n = 13,AIDS Research and Therapy 2007, 4:15 http://www.aidsrestherapy.com/content/4/1/15
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31.7%), and the rest (n = 7, 17.1%) received NRTIs only.
Comparison of the average number of medications
received by children from each ARV groups (Table 1) did
not reveal any statistically significant differences. Moreo-
ver, we found no association between the ARV regimen,
child's age and duration of the ARV treatment (Table 1).
Variation in the clinical, immune and virological presen-
tation of HIV disease and the mean number of mutations
was not significantly associated. The total number of
recorded HIV-1 isolate mutations did not correlate with
length of therapy or the child's age (Figure 1).
Individual analysis of the resistance mutations showed
that HIV-1 isolates from all but one of the infected chil-
dren treated with NRTI+PI regimens for 6 months devel-
oped different mutations in the RT and PR genes. Overall,
drug associated mutations were recorded in HIV-1 isolates
from 87.8% of children treated with NRTIs (n = 36/41),
66.7% treated with NNRTIs (n = 14/21), and 46.4%
treated with PIs (n = 13/28), P < 0.03. As shown in Figure
2, combined ARV regimens did not significantly influence
the incidence of NRTI and NNRTI associated mutations.
The primary (I-II class) PI mutations in the HIV-1 isolates
were twice as high in the children treated with
NRTI+NNRTI+PI as compared with the isolates from chil-
dren treated with NRTI+PI (60.0 % vs. 30.8%, P < 0.07).
The duration of PI treatment in the children who had a
history of ARV regimens including NRTI+ NNRTI+PI was
an average of 45.1+/-24 months as compared with 29.9+/
-19.2 months in those who were treated with NRTI+PI (P
= 0.08). A few non-classified mutations in the HIV-1
genome such as F 214L (n = 1, 3.3%), I64V (n = 3, 10.0%),
K10I (n = 3, 10.0%), R21I (n = 1, 3.3%), S68G (n = 2,
6.6%), and L214F (n = 1, 3.3%) were also observed in the
children treated with PI medications. Moreover, the HIV-
1 isolates from the NNRTI and PI naïve children showed
NNRTI (n = 4/20, 20.0%) and secondary (class III-IV) PI
associated mutations (n = 6/13, 46.1%).
As shown in Table 2, viremia ≥ 10,000 copies/mL was
recorded in almost all children with primary mutations in
the PR region (n = 12/13, 92.3%) as compared with only
HIV-1 drug resistance mutations correlated with age and duration of ARV therapy (in years) Figure 1
HIV-1 drug resistance mutations correlated with age and duration of ARV therapy (in years).
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50.0% (n = 14/28) of the HIV-1 infected children without
the primary mutation (PR-), P < 0.008. Age-specific CD4
counts and immune categories were distributed with an
almost similar frequency in the children with and without
the PI associated mutations. No differences in age at study
entry, length of previous ARV therapy and clinical stage of
disease were observed with respect to the resistance muta-
tions in the PR gene. We found that 3TC mutations and PI
secondary mutations were more frequently seen in HIV-1
isolates with primary mutations in the PR gene. However,
the presence of primary mutations in the PR gene (class I-
II) significantly increased the likelihood of PVL ≥ 10,000
copies/mL irrespective of the child's age, duration of ARV
therapy and presence of other mutations (Odds Ratio 1.7,
95% Confidence Interval 1.15, 2.52). At the same time,
primary mutations in the PR gene did not significantly
influence the severity of the clinical and immunological
presentation of HIV disease in the studied children (Table
2). Moreover, apart from the PI associated mutations,
there were no significant differences in the frequencies of
the NRTI and NNRTI associated resistance mutations in
the HIV-1 isolates in the children with PVL<10,000 cop-
ies/mL and >10,000 copies/mL (Figure 3).
Discussion
The introduction of combined therapy with reverse tran-
scriptase and protease inhibitors has resulted in a consid-
erable decrease in the HIV-1 related mortality [25].
Although the therapeutic regimens with the combined
medications increase the selective pressure against viruses,
they also subsequently induce the development of multi-
ple drug-resistant HIV-1 variants [26]. The present study
shows that NRTI -associated resistance mutations occur
nearly always in HIV-1 infected pediatric patients receiv-
ing NRTIs, but NNRTI and PI-associated mutations are
less likely to occur in children whose treatment includes
NNRTIs and PIs (87.8% vs. 66.7% vs. 46.1%, respectively,
P < 0.03). The rate of virus replication ≥ 10,000 copies/mL
is significantly associated with the PI medication resist-
ance mutations in the PR region at codons 10, 46, 54, 82
and 90 which are known to affect susceptibility to all cur-
rently FDA-approved PIs, and codon 30 (D30N), which
may also significantly affect the virological response [27].
In contrast, four or more mutations are required to over-
come the activity of PI medications in adults [28]. It is
possible that the thymidine-associated mutations (TAMs)
recorded in the HIV-1 infected children in the present
Presence of drug-specific HIV-1 mutations in relation to ARV  regimens Figure 2
Presence of drug-specific HIV-1 mutations in relation to ARV 
regimens.
Table 1: Demographic, clinical, and immunological data in association with the ARV treatment regimens
Parameters ARV treatment regimens
NRTI+NNRTI+PI
(n = 15)
NRTI+NNRTI
(n = 6)
NRTI + PI
(n = 13)
NRTIs
(n = 7)
Age of study entry (Mean+/-SD, yrs) 11.9+/-4.3 10.8+/-3.4 8.8+/-5.1 10.4+/-3.0
Length of treatment (Mean+/-SD, yrs) 7.8+/-3.1 6.7+/-2.3 5.1+/-2.8 5.8+/-2.7
Number of Medications
NRTI 3.7+/-0.7 3.3+/-1.0 3.1+/-1.0 2.7+/-1.1
NNRTI 1.1 +/-0.2 1.2+/-0.4 - -
PI 1.1+/-0.6 - 1.2+/-0.4 -
Clinical categories *
B 8 (53.3%) 3/5 (60.0%) 4 (30.8%) 3 (42.9%)
C 7 (46.7%) 2/5 (40.0%) 9(69.2%) 4 (57.1%)
Immune categories **
1 (no suppression) 10 (66.3%) 4 (66.7%) 7 (53.9%) 3 (42.9%)
2–3 (moderate/severe) 7 (33.3%) 2 (33.3%) 6 (46.1%) 4 (57.1%)
PVL (n, %)
<10,000 5 (33.3%) 4 (66.7%) 2 (15.4%) 4 (57.1%)
≥ 10,000 10 (66.7%) 2 (33.3%) 11 (84.6%) 3 (42.9%)
Number of mutations (Mean+/-SD) 5.7+/-3.8 3.5+/-1.6 4.7+/-3.2 3.7+/-2.3
*B-moderately, C-severely symptomatic 22,23
** Immune categories based on age-specific CD4+ T-lymphocyte count.22,23AIDS Research and Therapy 2007, 4:15 http://www.aidsrestherapy.com/content/4/1/15
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study may mediate resistance to multiple mutations unre-
lated to the NRTI treatment [29,30]. The mutations asso-
ciated with more than one NRTI may increase viral
replication in an additive manner [2,31,32] and NNRTI
associated mutations may intensify the rebound in the
HIV-1 RNA [33]. The observed association between the
higher PVL and resistance mutations in the PR region was
confirmed after controlling for mutations in the RT
regions. The persistent high-level of viral replication seen
in children with primary mutations in the PR gene may
increase the accumulation of multiple resistance muta-
tions [34-38] and therefore affect the efficacy of drug ther-
apy.
Although high-level virus production is associated with
CD4+ T-cell destruction in adults [39], no such associa-
tion was identified between viral replication and severity
of immune suppression in the children included in the
present study. Resino et al [40] identified the possibility of
CD4+ T-cell recovery despite virological failure resulting
in the discordant response in children. Moreover, viral
load suppression is not indispensable for recovery of
CD4+levels [41].
We have to acknowledge that insufficient drug potency,
pharmacological issues, and poor compliance could be
responsible for the anti-viral treatment failure [20], in
addition to the drug resistance mutations in the PR region
that were identified as a major predictor for the failure in
the suppression of viral replication in this study. Moreo-
ver, despite the disagreement in the literature [42-44],
medically directed treatment interruptions, which were
not analyzed in this study, may influence the virologic
and immunologic outcome as well as the development of
drug-resistant viral isolates. Long-term clinical and immu-
nologic follow up will be required in order to clarify the
predictive power of HIV-1 RNA plasma levels in the mon-
itoring of disease progression.
Conclusion
Despite the limitations, this study clearly demonstrates
that primary PR resistance mutations significantly
increase the likelihood for high viral replication in chil-
dren with moderate/severe HIV-1 infection. This raises
concern regarding early failure in drug susceptibility,
which may jeopardize the long-term clinical prognosis of
the HIV-1 infected pediatric patient.
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NNRTI therapy 9 (69.2%) 12 (42.9%)
TAMs mutations 10 (76.9%) 18 (64.3%)
3TC mutations 9 (64.2%) * 9 (32.1%)
NNRTI mutations 6 (46.1%) 12 (42.9%)
PI (secondary) 10 (76.9%) *** 15 (53.5%)
Clinical categories #
B 6 (46.1) 12/27 (44.4%)
C 7 (53.9%) 15/27 (55.6%)
Immune categories ##
1 (no suppression) 8 (61.5%) 16 (57.1%)
2–3 (moderate/severe) 5 (28.5%) 12 (42.9%)
PVL (n, %)
<10,000 1 (7.7%) ** 14 (50.0%)
≥ 10,000 12 (92.3%) 14 (50.0%)
Chi-square: * P < 0.02 ** P < 0.008 ***P < 0.0001
# Immune categories based on age-specific CD4+ T-lymphocyte 
count.22,23
## B-moderately, C-severely symptomatic 22,23AIDS Research and Therapy 2007, 4:15 http://www.aidsrestherapy.com/content/4/1/15
Page 6 of 7
(page number not for citation purposes)
study design and coordination.  CL carried out the data
collection.  AP  participated in study design, statistical
analysis, and preparation of manuscript.  All authors have
read and approved the final manuscript.
Acknowledgements
The authors would like to express their most sincere thanks to Margare-
tanne Murray for her assistance with this study.
References
1. Mitsuya H, Yarchoan R, Broder S: Molecular targets for AIDS
therapy.  Science 1990, 249:1533-1544.
2. Mansky LM, Pearl DK, Gajary LC: Combination of drugs and
drug-resistant reverse transcriptase results in a multiplica-
tive increase of human immunodeficiency virus type 1
mutant frequencies.  J Virol 2002, 76:9253-9259.
3. Iversen AK, Shafer RW, Wehrly K, Winters MA, Mullins JI, Chesebro
B, Merigan TC: Multidrug-resistant human immunodeficiency
virus type 1 strains resulting from combination antiretrovi-
ral therapy.  J Virol 1996, 70:1086-1090.
4. Brenner BG, Turner D, Wainberg MA: HIV-1 drug resistance: can
we overcome.  Expert Opin Biol Ther 2002, 2:751-761.
5. Winters MA, Coolley KL, Girard YA, Levee DJ, Hamdan H, Shafer
RW, Katzenstein DA, Merigan TC: A 6-basepair insert in the
reverse transcriptase gene of human immunodeficiency
virus type 1 confers resistance to multiple nucleoside inhibi-
tors.  J Clin Invest 1998, 102:1769-1775.
6. Schmit J-C, Van Laethem K, Ruiz L, Hermans P, Sprecher S, Sonner-
borg A, Leal M, Harrer T, Clotet B, Arendt V, Lissen E, Witvrouw M,
Desmyter J, De Clercq E, Vandamme AM: Multiple dideoxynucle-
oside analogue-resistant (MddNR) HIV-1 strains isolated
from patients from different European countries.  AIDS 1998,
12:2007-2015.
7. Schmit JC, Cogniaux J, Hermans P, Van Vaeck C, Sprecher S, Van
Remoortel B, Witvrouw M, Balzarini J, Desmyter J, De Clercq E, Van-
damme AM: Multiple drug resistance to nucleoside analogues
and nonnucleoside reverse transcriptase inhibitors in an effi-
ciently replicating human immunodeficiency virus type 1
patient strain.  J Infect Dis 1996, 174:962-968.
8. Shafer RW, Winters MA, Palmer S, Merigan TC: Multiple concur-
rent reverse transcriptase and protease mutations and
multidrug resistance of HIV-1 isolates from heavily treated
patients.  Ann Intern Med 1998, 128:906-911.
9. Torti C, Bono L, Gargiulo F, Uccelli MC, Quiros-Roldan E, Patroni A,
Paraninfo G, Tirelli V, Manca N, De Francesco MA, Perandin F, Carosi
G: Prevalence of drug resistance and newly recognized treat-
ment related substitution in the HIV-1 reverse transcriptase
and protease from HIV-positive patients naïve for anti-retro-
virals.  Clin Microbiol Infect 2004, 10:826-830.
10. Escoto-Delgadillo M, Vazquez-Valls E, Ramirez-Rodriguez M, Corona-
Nakamura A, Amaya-Tapia G, Quintero-Perez N, Panduro-Cerda A,
Torres-Mendoza BM: Drug-resistance mutations in antiretrovi-
ral-naive patients with established HIV-1 infection in Mexico.
HIV Med 2005, 6:403-409.
11. Fitzgibbon JE, Gaur S, Walsman SM, Janahi M, Whitley-Williams P,
John JF Jr: Emergence of drug resistance mutations in a group
of HIV-infected children taking nelfinavir-containing regi-
mens.  AIDS Res Hum Retroviruses 2001, 17:1321-1328.
12. Simonetti SR, Schatzmayr HG, Simonetti JP: Human immunodefi-
ciency virus type 1: Drug resistance in treated and untreated
Brazilian children.  Mem Inst Oswaldo Cruz, Rio de Janeiro 2003,
98:831-837.
13. Brindeiro PA, Brindeiro RM, Mortensen C, Hertogs K, De Vroey V,
Rubini NP, Sion FS, De Sa CA, Machado DM, Succi RC, Tanuri A:
Testing genotypic and phenotypic resistance in human
immunodeficiency virus type 1 isolates of clade B and other
clades from children failing antiretroviral therapy.  J Clin Micro-
biol 2002, 40:4512-4519.
14. Englund JA, Raskino C, Vavro C, Palumbo P, Ross LL, McKinney R,
Nikolic-Djokic D, Colgrove RC, Baker CJ, Pediatric AIDS Clinical Tri-
als Group Protocol 152 Team: Mutations linked to drug resist-
ance, human immunodeficiency virus type 1 biologic
phenotype and their association with disease progression in
children receiving nucleoside reverse transcriptase inhibi-
tors.  Pediatr Infect Dis J 2004, 23:15-22.
15. Hughes MD, Johnson VA, Hirsch MS, Bremer JW, Elbeik T, Erice A,
Kuritzkes DR, Scott WA, Spector SA, Basgoz N, Fischl MA, D'Aquila
RT: Monitoring plasma HIV-1 RNA levels in addition to CD4+
lymphocyte count improves assessment of antiretroviral
therapeutic response. ACTG 241 Protocol Virology Sub-
study Team.  Ann Intern Med 1997, 126:929-938.
16. O'Brien WA, Hartigan PM, Daar ES, Simberkoff MS, Hamilton JD:
Changes in plasma HIV RNA levels and CD4+ lymphocyte
counts predict both response to antiretroviral therapy and
therapeutic failure. VA Cooperative Study Group on AIDS.
Ann Intern Med 1997, 126:939-945.
17. Carpenter CC, Fischl MA, Hammer SM, Hirsch MS, Jacobsen DM,
Katzenstein DA, Montaner JS, Richman DD, Saag MS, Schooley RT,
Thompson MA, Vella S, Yeni PG, Volberding PA: Antiretroviral
therapy for HIV infection in 1997: Updated recommenda-
tions of the International AIDS Society-USA Panel.  JAMA
1997, 277:1962-1969.
18. Piatak M Jr, Saag MS, Yang LC, Clark SJ, Kappes JC, Luk KC, Hahn BH,
Shaw GM, Lifson JD: High levels of HIV-1 in plasma during all
stages of infection determined by competitive PCR.  Science
1993, 259:1749-1754.
19. Hirsch MS, Brun-Vezinet F, Clotet B, Conway B, Kuritzkes DR,
D'Aquila RT, Demeter LM, Hammer SM, Johnson VA, Loveday C,
Mellors JW, Jacobsen DM, Richman DD: Antiretroviral drug
resistance testing in adults infected with human immunode-
ficiency virus type 1: 2003 recommendations of an Interna-
tional AIDS Society-USA Panel.  Clin Infect Dis 2003, 37:113-128.
20. Johnson VA, Brun-Vezinet F, Clotet B, Conway B, D'Aquila RT, Dem-
eter LM, Kuritzkes DR, Pillay D, Schapiro JM, Telenti A, Richman DD:
Update of the drug resistance mutations in HIV-1: 2004.  Top
HIV Med 2004, 12:119-124.
21. Johnson VA, Brun-Vezinet F, Clotet B, Conway B, Kuritzkes DR, Pillay
D, Schapiro J, Telenti A, Richman D: Update of the drug resist-
ance mutations in HIV-1: 2005.  Top HIV Med 2005, 13:51-57.
22. Centers for Disease Control and Prevention: 1994 Revisedclassifi-
cation system for human immunodeficiency virus infection
in children less than 13 years of age.  MMWR Recomm Rep 1994,
43(RR-12):1-10.
23. Centers for Disease Control and Prevention: 1993 revised classifi-
cation system for HIV infection and expanded surveillance
case definition for AIDS among adolescents and adults.
MMWR Recomm Rep 1992, 41(RR-17):1-19.
24. Carpenter CC, Cooper DA, Fischl MA, Gatell JM, Gazzard BG, Ham-
mer SM, Hirsch MS, Jacobsen DM, Katzenstein DA, Montaner JS,
Richman DD, Saag MS, Schechter M, Schooley RT, Thompson MA,
Vella S, Yeni PG, Volberding PA: Antiretroviral therapy in adults:
updated recommendations of the International AIDS Soci-
ety-USA Panel.  JAMA 2000, 283:381-390.
25. Palella FJ Jr, Delaney KM, Moorman AC, Loveless MO, Fuhrer J, Sat-
ten GA, Aschman DJ, Holmberg SD: Declining morbidity and
mortality among patients with advanced human immunode-
ficiency virus infection.  N Engl J Med 1998, 338:853-860.
26. Little SJ, Holte S, Routy JP, Daar ES, Markowitz M, Collier AC, Koup
RA, Mellors JW, Connick E, Conway B, Kilby M, Wang L, Whitcomb
JM, Hellmann NS, Richman DD: Antiretroviral-drug resistance
among patients recently infected with HIV.  N Engl J Med 2002,
347:385-394.
27. Manfredi R, Calza L: HIV genotypic mutation selectively
induced by the protease inhibitor nelfinavir at codon 30.
Case series and consequences for antiretroviral manage-
ment.  Infez Med 2002, 10:151-156.
28. Condra JH, Schleif WA, Blahy OM, Gabryelski LJ, Graham DJ, Quin-
tero J, Rhodes A, Robbins HL, Roth E, Shivaprakash M, Titus D, Yang
T, Tepplert H, Squires KE, Deutsch PJ, Emini EA: In vivo emer-
gence of HIV-1 variants resistant to multiple protease inhib-
itors.  Nature 1995, 374:569-671.
29. Lange J: A rational approach to the selection and sequencing
of nucleoside/nucleotide analogues: a new paradigm.  Antivir
Ther 2001, 6(Suppl 3):45-54.
30. Soriano V, de Mendoza C: Genetic mechanisms of resistance to
NRTI and NNRTI.  HIV Clin Trials 2002, 3:237-248.
31. Jewell NA, Chen R, Raices R, Mansky LM: Nucleoside reverse
transcriptase inhibitors and HIV mutagenesis.  J Antimicrob
Chemother 2003, 52:547-550.Publish with BioMed Central    and   every 
scientist can read your work free of charge
"BioMed Central will be the most significant development for 
disseminating the results of biomedical research in our lifetime."
Sir Paul Nurse, Cancer Research UK
Your research papers will be:
available free of charge to the entire biomedical community
peer reviewed and published  immediately upon acceptance
cited in PubMed and archived on PubMed Central 
yours — you keep the copyright
Submit your manuscript here:
http://www.biomedcentral.com/info/publishing_adv.asp
BioMedcentral
AIDS Research and Therapy 2007, 4:15 http://www.aidsrestherapy.com/content/4/1/15
Page 7 of 7
(page number not for citation purposes)
32. Mansky LM: Mutagenic outcome of combined antiviral drug
treatment during human immunodeficiency virus type 1 rep-
lication.  Virology 2003, 307:116-121.
33. Deeks SG: International perspectives on antiretroviral resist-
ance. Nonnucleoside reverse transcriptase inhibitor resist-
ance.  J Acquir Immune Defic Syndr 2001, 26(Suppl 1):S25-33.
34. Gulick RM, Mellors JW, Havlir D, Eron JJ, Gonzalez C, McMahon D,
Richman DD, Valentine FT, Jonas L, Meibohm A, Emini EA, Chodake-
witz JA: Treatment with indinavir, zidovudine, and lamivu-
dine in adults with human immunodeficiency virus infection
and prior antiretroviral therapy.  N Engl J Med 1997,
337:734-739.
35. Mansky LM, Temin HM: Lower in vivo mutation rate of human
immunodeficiency virus type 1 than that predicted from the
fidelity of purified reverse transcriptase.  J Virol 1995,
69:5087-5094.
36. Coffin JM: HIV population dynamics in vivo: Implications for
genetic variation, pathogenesis, and therapy.  Science 1995,
267:483-489.
37. Bangsberg DR, Moss AR, Deeks SG: Paradoxes of adherence and
drug resistance to HIV antiretroviral therapy.  J Antimicrob
Chemother 2004, 53:696-699.
38. Aceti A, Carosi G: Genotypic resistance tests in the manage-
ment of the HIV-infected patient at virological failure.  Scand
J Infect Dis 2003, 35(suppl 106):61-66.
39. Wei X, Ghosh SK, Taylor ME, Johnson VA, Emini EA, Deutsch P, Lif-
son JD, Bonhoeffer S, Nowak MA, Hahn BH, Saag MS, Shaw GM:
Viral dynamics in human immunodeficiency virus type 1
infection.  Nature 1995, 373:117-122.
40. Resino S, Galan I, Perez A, Leon JA, Seoane E, Gurbindo D, Munoz-
Fernandez MA: HIV-infected children with moderate-severe
immune-suppression; changes in the immune system after
highly active antiretroviral therapy.  Clin Exp Immunol 2004,
137:570-577.
41. Resino S, Resino R, Leon JA, Bellon JM, Martin-Fontelos P, Ramos JT,
Gurbindo-Gutierrez D, de Jose MI, Ciria L, Munoz-Fernandez MA:
Impact of long-term viral suppression in CD4+ recovery of
HIV-children on Highly Active Antiretroviral Therapy.  BMC
Infect Dis 2006, 6:10-16.
42. Martinez-Picado J, Frost SD, Izquierdo N, Morales-Lopetegi K, Marfil
S, Puig T, Cabrera C, Clotet B, Ruiz L: Viral evolution during
structured treatment interruptions in chronically human
immunodeficiency virus-infected individuals.  J Virol 2002,
76:12344-12348.
43. Deeks SG, Wrin T, Liegler T, Hoh R, Hayden M, Barbour JD, Hell-
mann NS, Petropoulos CJ, McCune JM, Hellerstein MK, Grant RM:
Virologic and immunologic consequences of discontinuing
combination antiretroviral-drug therapy in HIV-infected
patients with detectable viremia.  N Engl J Med 2001,
344:472-480.
44. Boucher S, Recordon-Pinson P, Neau D, Ragnaud J-M, Titier K, Faure
M, Fleury H, Masquelier B: Clonal analysis of HIV-1 variants in
proviral DNA during treatment interruption in patients with
multiple therapy failures.  J Clin Virol 2005, 34:288-294.